Writer I was reading one of your previous posts regarding the 90...

Writer I was reading one of your previous posts regarding the 90 million Euro JV deal UNI has going on in Croatia and how you talked about the savings in transport for the prefill syringe having a strategic manufacturing locations in different parts of the world.

This brings me to our prefill syringe and what a financial saving it will be to the pharmaceutical company in transport and storage costs, being a half to quarter of the size of the present unit, given the growing cost of transport, a reduction by 50 to 75% is a sizable transport saving more so today than any other time with industries trying to contain costs.

General question to fellow investors:

(1) How much will FDA and sales for the 1ml insulin syringe add to the SP?
(2) How much will the pharmaceutical licence fee be?
(3) And what do you expect the SP to run too with lic fee?